Donna Gustafson, a pancreatic cancer patient, became the first recipient of a personalized mRNA vaccine in a clinical trial exploring this novel immunotherapy. This groundbreaking approach aims to bolster the immune system, specifically T cells, to seek and destroy lingering cancer cells, thereby preventing recurrence. Early trial data, presented at the American Association for Cancer Research, indicates that patients who mount an immune response to the vaccine, like Gustafson, show significantly improved long-term survival rates. While cautioning that results are preliminary and derived from a small patient group, researchers are optimistic about the potential of these personalized mRNA vaccines to combat difficult-to-treat cancers like pancreatic cancer.
Read More
The Food and Drug Administration (FDA) has refused to review Moderna’s experimental flu shot, mRNA-1010, citing issues with the study design despite previous agency approval. Moderna stated the FDA did not identify any safety or efficacy concerns and plans to meet with the agency to discuss a path forward. This decision, which contrasts with prior feedback, occurs amidst broader shifts in U.S. vaccine regulation influenced by prominent vaccine skeptic Robert F. Kennedy Jr. and the return of FDA vaccine regulator Vinay Prasad, who has advocated for tighter vaccine rules. Despite this setback, Moderna’s stock saw a slight dip, but the company expects approval for its flu shot by late 2026 or late 2027, pending international reviews.
Read More
A recent study published in the journal Nature revealed a surprising link between COVID-19 mRNA vaccines and improved cancer outcomes. Researchers found that patients with melanoma and lung cancer who received either the Pfizer or Moderna COVID-19 vaccine in conjunction with immunotherapy experienced significantly higher survival rates compared to those who did not. This effect was observed even in patients with tumors that typically do not respond well to immunotherapy. The study suggests that the mRNA vaccines act as an alarm, triggering the immune system to recognize and kill tumor cells, potentially turning “cold” tumors “hot.” A nationwide clinical trial is planned to further investigate the inclusion of COVID-19 mRNA vaccines in standard cancer treatment, with the hope of extending the benefits of immunotherapy to a wider range of patients.
Read More
John Q. Hosedrinker